Physician profile
Lance C Lemon
NPI 1669490702
$5,694.94
in general payments reported to CMS, 2019-2025
27 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $213 · 2021: $692 · 2022: $851 · 2023: $1,376 · 2024: $706 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,074 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,073.93 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,487.63 | 2019-2025 | Hydrus Microstent, Rocklatan, Clareon |
| Bausch & Lomb Americas INC. | $534.39 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $520.92 | 2020-2025 | Acthar |
| Abbvie INC. | $484.08 | 2022-2025 | |
| Allergan, INC. | $470.67 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $344.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $330.63 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $196.61 | 2022-2025 | Purified Cortrophin Gel, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $162.29 | 2019-2021 | |
| Shire North American Group INC | $151.76 | 2019 | |
| Oyster Point Pharma, INC. | $129.16 | 2022-2024 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $119.74 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $114.88 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $100.32 | 2021-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Janssen Biotech, INC. | $99.16 | 2023 | Simponi, Simponi Aria, Remicade |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $84.69 | 2020-2024 | Tecnis Iol, Tecnis Iol |
| Rayner Intraocular Lenses Limited | $64.63 | 2023-2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Glaukos Corporation | $62.24 | 2021-2023 | |
| Dompe US, INC. | $37.86 | 2024-2025 | Oxervate |
| Ivantis, INC | $37.06 | 2019 | |
| Sight Sciences, INC. | $34.46 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Omeros Corporation | $29.70 | 2019 | |
| Sun Pharmaceutical Industries INC. | $23.78 | 2021-2022 | |
| Rxsight INC | $22.80 | 2021 | |
| Genentech USA, INC. | $20.72 | 2024 | Vabysmo |
| Biotissue Holdings INC. | $15.55 | 2024 | |
| Ocular Therapeutix, INC. | $14.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Lemon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.